David E. Moller

Dr. David Moller has extensive experience in biopharmaceutical R&D across a range of therapeutic areas and modalities. He currently serves as Chief Scientific Officer at Poxel SA, a clinical-stage biotechnology company pursuing novel therapies for rare metabolic diseases. David also led R&D efforts as CSO at Sigilon Therapeutics; this technology employs immune-privileged engineered cell implants for the treatment of chronic diseases – including hemophilia and lysosomal storage diseases.

David’s past experience includes 20 years leading R&D efforts at Merck and Eli Lilly. While Vice President, Metabolic Disorders at Merck, David’s team discovered and delivered several key additions to the pipeline – including sitagliptin (JanuviaTM). As Vice President Endocrine-Cardiovascular and Clinical Investigation at Lilly, David’s team delivered numerous additions to the pipeline including dulaglutide (TrulicityTM), novel insulins, and dual incretin agonists (tirzepatide), and several Phase II-III molecules targeting musculoskeletal, urologic and cardiorenal disorders. While leading global discovery and development efforts in these areas, David had additional responsibility for scientific assessments of BD projects and execution of partnerships involving clinical stage programs, preclinical projects, and technology platforms. At Eli Lilly, David also served as Vice President, Business Development – in this role, he established and led the Emerging Technology and Innovation team; a Boston based effort focusing on access to early phase external innovation across all disease areas including oncology and novel platforms – plus establishing and leveraging flexible funding models and venture capital partnerships. David has also held additional recent roles including as a SAB member at Axcella Health and as a strategic advisor to TVM Capital.